Abstract
Trials of active nonspecific immunotherapy as adjuvant therapy for tumors have increased dramatically in number since the results that have been published on acute leukemia [6] and melanoma [3, 5, 7–9]. In spite of considerable work [4], the justification of immunotherapy in cancerology has made hardly any progress, and the results remain controversial [10]. In numerous cases, the actual conditions of the trials undertaken do not seem satisfactory. An example is the application of immunotherapy to patients still carrying massive tumoral growths, despite the fact that this contravenes experimental data [1] and also discredits the interpretation because of many other intervening factors; furthermore, the influence of the symptomatic treatments necessarily associated confuses the observed results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Reference
Amiel, J. L., Berardet, M.: Factor time for active immunotherapy after cytoreductive chemotherapy. Eur. J. Cancer. 10, 89 (1974).
Amiel, J. L., Sancho, H., Vandenbrouck, C.: Note préliminaire sur un essai d’immunotherapie active par le BCG pour des tumeurs ORL. Bull. Cancer. 63, 287–288 (1976).
Eibler, F. R., Morton, D. L., Holmes, E. D., Sparks, F. C., Ramming, K. P.: Adjuvant immunotherapy with BCG in treatment of regional-lymphnode metastasis from malignant melanoma. N. Engl. J. Med. 294, 237–240 (1976).
International Registry of Tumor Immunotherapy: Compendium of Tumor Immunotherapy Protocols. N° 5. September 1977.
Jewell, W. R., Thomas, J. H., Sterchi, J. M., Morse, P. A., Humphrey, L. J.: Critical Analysis of Treatment of Stage II en Stage III Melanoma Patients with immunotherapy. Ann. Surg. 183, 543–549 (1976).
Mathe, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hryat, M. de Vassal, F.: First results of active immunotherapy in the treatment of acute lymphoblastic leukaemia in man. Lancet 1969/1, 697.
McCulloch, P. B., Dent, P. B., Blajchman, M., Muirhead, W. M., Price, R. A.: Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. CMA J. 117 (1977).
Morton, D. L., Eilber, F. R., Holmes, E. C., Sparks, F. C., Ramming, K. P.: Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol. Immunother. 1, 93–98 (1976).
Newlands, E. S., Oon, C. J., Roberts, J. T., Elliott, P., Mould, R. F., Topham, C., Madden, F. J. F., Newton, K. A., Westbury, G.: Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br. J. Cancer. 34, 174 (1976).
UICC: Controlled Therapeutic Trials in Cancer. Technical Report Series 14, Geneva 1974.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Amiel, J.L. et al. (1979). First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors. In: Bonadonna, G., Mathé, G., Salmon, S.E. (eds) Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. Recent Results in Cancer Research, vol 68. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81332-0_48
Download citation
DOI: https://doi.org/10.1007/978-3-642-81332-0_48
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81334-4
Online ISBN: 978-3-642-81332-0
eBook Packages: Springer Book Archive